Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia
TO THE EDITOR Acquired hemophilia due to factor VIII autoantibodies is a rare disease with an estimated annual incidence of 1/10 6 . Anti-factor VIII antibodies can occur in conjunction with post-partum, autoimmune disease, the use of medications or malignant conditions such as chronic lymphocytic leukemia (CCL). An excess of autoimmune phenomena is a hallmark of CLL, but only rare cases of CCL-associated anti-factor VIII antibodies have been described. 1 Hemostatic treatments, such as human factor VIII, porcine factor VIII or recombinant factor VIIa, and non-long-lasting treatments, like plasmapheresis or high-dose intravenous immunoglobulins (IVIG), used to control bleeding, are very expensive. Long-term suppression of the antibody depends on immunosuppressive therapy: prednisone alone for low-titer factor inhibitor, continuous low-dose oral cyclophosphamide and prednisone in other cases. 2 The interval between the beginning of the treatment and the efficiency is a major prognosis, but also economic, factor.
A 65-year-old woman with an 11-year history of CD5 + kappa B cell-CLL (Rai stage O, Binet stage A) developed a 20 cm diameter retroperitoneal hematoma and other spontaneous soft tissue hemorrhages. Hemoglobin was 3 g/dl. Her activated partial thromboplastin time was 103 s (normal: 33). Factor VIII level was 4% while factor VIII antibody was 20 Bethesda units (BU). She was treated with recombinant factor VIIa for 5 days. She then received a first course of fludarabine (30 mg/m 2 on day 1 to 3) and cyclophosphamide (1000 mg/m 2 on day 1), and porcine factor VIII for 4 days. Plasmapheresis was done on day 10 and 11, when factor VIII level was 10% (8.6 BU). Factor VIII was 13% (3.9 BU) after plasma exchange. She then received recombinant factor VIII, until day 19 of treatment. Factor VIII level remained above 30% thereafter. She was subsequently treated monthly with fludarabine and cyclophosphamide for 2 months. Factor VIII inhibitor remained under 5 BU after day 12 of treatment and undetectable at day 60. Simultaneous PML/RAR␣ and AML 1/ETO gene rearrangements in a patient with acute myeloid leukemia TO 
THE EDITOR
Relapse of acute promyelocytic leukemia (APL) following successful all-trans retinoic acid (ATRA)/chemotherapy treatment with a different subtype of acute myeloid leukemia (AML) is a rare event. Both the clonal and the temporal relationship between APL and the secondary AML subtype are usually obscure. [1] [2] [3] [4] Recently, a chimeric M3:M2 case of acute promyelocytic leukemia was presented. Fludarabine is a new purine analogue with major activity in the treatment of CLL. 3 Inhibition of DNA and RNA synthesis and the possibly related induction of apoptosis are the presumed mechanisms of action. Because T cell immunosuppression is a consequence, purine analogs could be successful in various autoimmune diseases, like rheumatoid arthritis, 4 even if autoimmune cytopenia, mostly hemolytic anemia, induced by fludarabine has been reported. 5 Our observation illustrates acquired hemophilia associated with CLL might be rapidly improved and cured with fludarabine and cyclophosphamide, without corticosteroids.
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Acquired factor VIII inhibitor at the onset of prolymphocytic leukemia. Leukemia 1996; 10: 1557-1558. history was unremarkable. The immunophenotype of the blasts was CD34: 9%, CD33: 90%, CD13: 50%, CD14: 6%, CD15: 72%, CD19: 2%, HLA-DR: 35%, CD33/CD34: 9%, CD33/CD15: 65% RT-PCR performed 1 day after the diagnosis as described in Ref. 6 identified PML/RAR␣ chimeric transcripts of the bcr1 type (L-form). The patient attained complete remission with a combined course of ATRA and idarubicin. About 20 days after the diagnosis, conventional cytogenetic analysis revealed the presence of t(8;21) and no other karyotypic abnormalities; then, the diagnostic sample was re-examined by RT-PCR and found positive for both PML/RAR␣ and AML1/ETO chimeric transcripts. The patient received a second induction course of idarubicin and Ara-C (1 g/m 2 every 12 h over days 1-4) and two courses of consolidation chemotherapy with high-dose Ara-C (3 g/m 2 every 12 h over days 1, 3 and 5). RT-PCR was performed after each consolidation course and detected only AML 1/ETO transcripts. In August 1997, the patient relapsed with FAB-M2 AML. Karyotypic analysis revealed t(8;21) and RT-PCR was positive only for AML 1/ETO transcripts; the immunopheontype of the blasts was: CD34: 92%, CD33: 2%, CD13: 56%, CD15: 3%, CD56: 36%, CD19: 60%, HLA-DR: 98%, CD34/CD56: 34%. The patient attained complete remission with idarubicin and Ara-C and then, in November 1997, she underwent allogeneic bone marrow transplantation from an HLAcompatible sibling. However, she relapsed again in June 1998 with FAB-M2 AML and died 2 months later.
Conventional cytogenetics detect t(15;17) in APL with a sensitivity of 70-80%; even when cytogenetic analysis fails, as seems to have happened in our patient at diagnosis, PML/RAR␣ fusion is always identified by fluorescence in situ hybridization (FISH) or molecular biology techniques and denotes patients who are likely to respond to ATRA treatment. Based on the available cytogenetic data, it is not possible to discriminate whether the two genetic aberrations identified in our patient by RT-PCR were present in the same or in distinct clones. However, if the first alternative was true, one would expect RT-PCR to detect PML/RAR␣ chimeric transcripts along with AML1/ETO transcripts. Whatever the case, in agreement with Bonomi et al, 5 it is reasonable to speculate that combined ATRA/chemotherapy eliminated the APL clone but did not prevent progression or recurrence of the M2 clone that already existed at disease presentation. In conclusion, we feel that the similarities between the case reported by Bonomi et al and our patient are striking. Furthermore, the data presented above justify calling our case a M3:M2 chimeric AML.
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First and Second Departments Unfortunately, this information cannot be further extended to AML3 leukemias as we present here evidence that fresh AML3 leukemic cells, bearing the t(15;17) and molecularly defined as bearing either the short PML-RAR␣ (bcr3) or long PML-RAR␣ (bcr1) fusion genes are HLA A-B-C positive (79.3% ± 17.5% and 83.6% ± 12.9%, respectively). Likewise, the original NB4 cell line and the one currently used in our laboratory express HLA A-B-C (80%, range 70%-85%) as reported in the initial publication. 2 Moreover, upon differentiation with all-trans retinoic acid, no modulation of the percentage of positive cells or the intensity of labelling (correlating with the number of sites expressed at the cell surface) was observed ( Figure 1 and data not shown).
The great number of PML isoforms identified 3 suggest maybe multiple tissue-specific functions for PML. PML-RAR␣ transcripts expressed in APL patients are relatively homogenous (PML breakpoint observed in intron 6, bcr1 or in intron 3, bcr3 subtype). A patient with a t(15;17) translocation resulting in fusion gene which mimicks the mutated PML-F12 isoforms fused to the RAR␣ gene would be extremely rare. However it is not impossible that such a mutation may be either obtained or predominant in vitro and present in the NB4 clone on which Zheng et al have based their results. Indeed, though the PML-F12 isoform is apparently expressed in normal tissues, the mutant form was isolated from a tumor cell line.
